Martha Terris, MD
Witherington Distinguished Chair, Urology
- Augusta GA UNITED STATES
Dr. Terris specializes in urologic cancers, including prostate cancer, kidney cancer, adrenal masses, bladder cancer and testicular cancer.
Contact More Open optionsSpotlight
June 10, 2019
2 min
Multimedia
Social
Biography
Dr. Terris' clinical interests include urologic oncology, nerve-sparing radical prostatectomy, partial and complete kidney removal for cancer, testicular cancer surgery, adrenal cancer surgery, and intestinal bladder substitution (no external stoma) with radical cystectomy. She also offers robotic surgery and bladder substitution surgery.
Her research interests include prostate biopsy techniques, prostate cancer risk factors, bladder cancer risk factor, nutritional therapies for prostate cancer, and new imaging techniques for urologic cancers.
Areas of Expertise
Education
Mississippi State University
Bachelor's Degree
University of Mississippi School of Medicine
Doctor of Medicine
Duke University Medical Center
Residency, General Surgery
Stanford University Medical Center
Residency, Urology
Stanford University Medical Center
Fellow, Urologic Oncology
Affiliations
- American Urological Association
- American Society of Clinical Oncologists
- Association of Women Surgeons
- Founding member, Georgia Chapter of Association of Women Surgeons
- American College of Surgeons
- Editorial board of the Journal of Urology
- Trustee of the American Board of Urology
Links
Media Appearances
Bladder Cancer Awareness: MCG making strides to improves testing and outcomes
News Channel 6 tv
2019-05-20
Bladder cancer is one of the most common cancers, impacting nearly 70,000 adults in the US each year. Dr. Martha Terris and Dr. Vinata Lokeshwar from the Medical College of Georgia are focused on the disease鈥檚 diagnosis and treatment, and share their expertise with viewers of The Means Report.
Looking for the 鈥渨hy鈥� in bladder cancer deaths for African American patients
Jagwire online
2019-02-22
It has long been known that African Americans die at higher rates from bladder cancer than do European Americans. According to findings shared in the January publication of the American Cancer Society鈥檚 Cancer, differences in the way tumor cells in African American patients metabolize proteins and nutrients could be the key to unlocking why.
da Vinci XI robotic system offers new surgical options for patients
Jagwire online
2019-03-01
When it comes to performing complex surgery, even the best surgeon may need a helping hand, even if that hand is cold, metal and strong enough to hold the smallest of instruments. For that reason, 黑料正能量 Health is introducing the da Vinci XI into the operating room.
Prostate cancer awareness
The Augusta Chronicle print
2017-09-10
Prostate cancer may be the most common form of cancer in men and the third leading cause of cancer death in men, but women need to know they have an important role to play in the health of the men in their lives.
59th Annual AUA Award Winners Announced 2022 Awards Recognize Top Urologists, Honor Service to Specialty and Society
PR Newswire online
The American Urological Association (AUA) announced today the list of its 2022 award recipients. The honorees will be recognized at the Association's Annual Meeting in New Orleans, LA next May marking the 59th anniversary of the awards program. The ceremony will celebrate physician researchers and educators for their contributions to the field of medicine, the specialty of urology and the AUA. The following awards will be presented: AUA Announces 59th AUA Annual Award Winners AUA Announces 59th AUA Annual Award Winners Ramon Guiteras Award: The Ramon Guiteras Award is presented annually to an individual for outstanding contributions to the art and science of urology. Glenn M. Preminger, MD will receive this award for outstanding service to the AUA and for pioneering and innovative work in the field of endourology.
Toward a New Staging System for Prostate Cancer, and Why it Matters
Michigan Health Lab online
2020-12-22
Doctors and biostatisticians at the University of Michigan Rogel Cancer Center have led the development and validation of a staging system to better predict outcomes and inform treatment decisions for men diagnosed with non-metastatic prostate cancer. Although it is one of the most common cancers worldwide, prostate cancer remains one of the few major cancers for which the familiar, numerical staging system 鈥� ranging from stage 1 to stage 4 鈥� has not been adopted into national guidelines for treatment or for the testing of new medicines in clinical trials.
Articles
Decreasing suicide risk among patients with prostate cancer: Implications for depression, erectile dysfunction, and suicidal ideation screening.
Urology OncologyKlaassen Z1, Arora K2, Wilson SN3, King SA3, Madi R3, Neal DE Jr.3, Kurdyak P4, Kulkarni GS5, Lewis RW3, Terris MK3
2018-02-01
Prostate cancer is the most common malignancy among males, accounting for 19% of cancers, and the third most common cancer-related cause of death. Suicide rates in the United States have increased among males over the last decade. Further, suicide rates are higher in oncology patients, including patients with prostate cancer, compared to the general population. The objective of this article is to review the current literature and address the relationship between prostate cancer, depression, erectile dysfunction, and suicidal ideation.
Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy: A Safe Surgical Technique with Superior Continence Outcomes
Journal of EndourologySayyid Rashid K. , Simpson William G. , Lu Caroline , Terris Martha K. , Klaassen Zachary , and Madi Rabii
2017-12-01
To report early operative outcomes and assess continence in 100 consecutive patients who underwent Retzius-sparing robotic-assisted laparoscopic radical prostatectomy (RALP). Materials and Methods: This was a prospective, single-center, consecutive case series of 100 and 100 patients undergoing a Retzius-sparing and a conventional RALP, respectively, by a single surgeon between March 2015 and April 2017.
Statin medication use and the risk of biochemical recurrence after radical prostatectomy
Journal CancerRobert J. Hamilton, Lionel L. Banez, William J. Aronson, Martha K. Terris, Elizabeth A. Platz, Christopher J. Kane, Joseph C. Presti, Christopher L. Amling, Stephen J. Freedland
2010-07-15
Although controversial, evidence suggests statins may reduce the risk of advanced prostate cancer (PC), and recently statin use was associated with prostate-specific antigen (PSA) reductions among men without PC. The authors sought to examine the association between statin use and PSA recurrence after radical prostatectomy (RP).
Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.
The Journal of UrologyHodge KK, McNeal JE, Terris MK, Stamey TA
1989-07-01
Random systematic ultrasound guided transrectal core biopsies of the prostate were compared to directed biopsies of specific hypoechoic defects in 136 men with abnormal prostates on digital rectal examination. Prostate cancer was diagnosed in 83 of 136 patients (62 per cent). In 80 of 83 individuals (94 per cent) the cancer was detected by random systematic biopsies alone. Of 57 men in whom random systematic and directed biopsies were obtained the results of biopsy agreed in 86 per cent, while in 9 per cent random systematic biopsies found cancers missed by directed biopsies and in 5 per cent directed biopsies diagnosed cancers missed by random systematic prostate biopsies. Ultrasound guided random systematic biopsy is simple and easily learned. When combined with additional directed biopsies of the rare hypoechoic areas not included in the pattern of systematic sampling, it provides a highly accurate means to diagnose prostate cancer, minimizing observer and sampling errors. This technique of prostate mapping with 6, 1.5 cm. cores provides valuable additional information on cancer volume, Gleason grade and the potential location of surgically positive margins, all without compromising the operation or the chance for a surgical cure.
The American Board of Urology: Striving for Inclusive Excellence
American Urological AssociationCheryl T. Lee, MD; Martha Terris, MD; Christopher Amling, MD; David Bock, MD; J. Brantley Thrasher, MD, FACS; Eila Skinner, MD
2022-04-01
The mission of the American Board of Urology (ABU) is to act for the benefit of the public by establishing and maintaining standards of certification for urologists and working with certified urologists to achieve lifelong learning to ensure the delivery of high-quality, safe and ethical urological care. Unwritten within this mission is the ABU鈥檚 commitment to fostering and sustaining a diverse workforce to fully serve every individual with a urological condition. As part of its strategic goals, the ABU has committed itself to inclusive excellence by integrating diversity, equity and inclusion into the fabric of its organizational structure in pursuit of certifying urologists capable of achieving real health equity in our field.
Oncocytoma-Related Gene Signature to Differentiate Chromophobe Renal Cancer and Oncocytoma Using Machine 黑料正能量
National Library of MedicineKhaled Bin Satter, Paul Minh Huy Tran, Lynn Kim Hoang Tran, Zach Ramsey, Katheine Pinkerton, Shan Bai, Natasha M. Savage, Sravan Kavuri, Martha K. Terris, Jin-Xiong She, and Sharad Purohit
2022-01-11
Chromophobe renal cell carcinoma (chRCC) and oncocytoma (RO) are renal tumor types originating from alpha intercalated cells of the collecting ducts of the kidney comprising 8鈥�12% of all renal neoplasms. Histologically, chRCC is composed of sheets of cells with well-defined cell borders that have darker cytoplasm than conventional clear cell carcinoma and peri-nuclear halos. ChRCC, a malignant tumor, requires surgical intervention
Impact of early hypothalamic-pituitary-gonadal axis maturation on prostate cancer: cross-sectional analysis of a Veterans affairs cohort
National Library of MedicineRimaz M. Khadir, Rashid K. Sayyid, Brian Matthews, Sherita A. King, , and Martha K. Terris
2021-08-10
It has been hypothesized that earlier onset of puberty, and thus a more prolonged exposure to high androgen levels, increases risk of prostate cancer development. Our objective was to determine whether earlier age of first shave and height, as surrogates of pubertal onset, were associated with risk of prostate cancer diagnosis. A prospectively collected outcomes registry of patients presenting for a prostate biopsy at the Charlie Norwood Veterans Affair Medical Center in Augusta, GA between July 1995 and June 2016 was utilized. The associations between age of first shave and height, each, and risks of a positive prostate biopsy, high grade cancer, and high volume disease were evaluated using univariable and multivariable logistic regression analysis, controlling for baseline patient demographic and oncologic characteristics.